The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions
Open Access
Abstract
Phage therapy has been revisited as a biologically based strategy to tackle the escalating global crisis of multidrug-resistant (MDR) bacterial infections. Distinct from conventional antibiotics, bacteriophages target specific bacterial strains precisely, replicate locally at infection sites, penetrate bacterial biofilms, and exert synergistic effects with multiple antimicrobial agents. These inherent mechanistic advantages minimize collateral damage to the host’s commensal microbiota. However, existing regulatory frameworks—originally established for chemically synthesized, mass-produced drugs—fail to accommodate personalized, living biological phage products, leading to uncertain approval pathways and inconsistent manufacturing supervision. Clinical experience of phage therapy is predominantly derived from compassionate-use cases via multiple administration routes, including intravenous, inhaled, and topical delivery. This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneous bacterial populations. Current clinical practice demonstrates that phage therapy exhibits acceptable safety profiles across intravenous, inhaled, and topical administration routes, with promising therapeutic outcomes in otherwise untreatable MDR infections. Nevertheless, stable and reproducible clinical outcomes are hindered by multiple scientific and operational obstacles: the absence of unified standards for phage production and quality control, insufficient understanding of route-dependent pharmacokinetics, the imperative demand for rapid pathogen identification to enable precise phage matching, and the limited efficacy of fixed-cocktail regimens against genetically diverse clinical isolates. The successful integration of phage therapy into routine clinical practice relies on coordinated progress in diagnostic infrastructure construction, GMP-compliant phage repository establishment, international regulatory harmonization, and high-quality evidence generation through well-designed clinical trials. Rather than serving as a universal substitute for antibiotics, phage therapy is best implemented as a precision complementary component within comprehensive antimicrobial stewardship strategies.Keywords
Funding Information
- Yunnan Provincial Science and Technology Department (202201AU070003)
This publication has 66 references indexed in Scilit:
- Changes to virus taxonomy, the international code of virus classification and nomenclature, and the ICTV statutes ratified by the International Committee on Taxonomy of Viruses (2025)Archives of Virology, 2025
- Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agentMolecular Biology Reports, 2025
- The Host R‐M Systems Change the Host Range of Staphylococcus Phage EBHTMicrobiologyopen, 2025
- CRISPR-Cas systems in combating antimicrobial resistance: which system to choose? A systematic reviewWorld Journal of Microbiology and Biotechnology, 2025
- Efficacy of precisely tailored phage cocktails targeting carbapenem-resistant Acinetobacter baumannii reveals evolutionary trade-offs: a proof-of-concept studyEBioMedicine, 2025
- Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- The Future of Microbiome TherapeuticsDrugs, 2025
- Bacteriophage Receptor Recognition and Nucleic Acid Transfer2024
- Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommitteeArchives of Virology, 2023
- Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due toStaphylococcus aureusJAMA Otolaryngology–Head & Neck Surgery, 2019